Wybrane zagadnienia dotyczące lakozamidu Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
cze 30, 2024
Słowa kluczowe:
lakozamid, mechanizm działania, skuteczność, tolerancja
##plugins.themes.bootstrap3.article.main##
Abstrakt
Lakozamid to lek przeciwpadaczkowy nowej generacji o unikalnym mechanizmie działania, nasilającym powolną inaktywację kanałów sodowych. Jest stosowany w monoterapii i terapii dodanej napadów ogniskowych u dorosłych i dzieci od 2. r.ż. Wysoka skuteczność, dobra tolerancja oraz korzystne właściwości farmakokinetyczne lakozamidu pozwalają na zastosowanie go w wielu populacjach pacjentów, m.in. u pacjentów starszych, u osób z wielochorobowością somatyczną i psychiatryczną czy guzami mózgu.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Bosak, M. (2024). Wybrane zagadnienia dotyczące lakozamidu. Medycyna Faktów , 17(2(63), 283-287. https://doi.org/10.24292/01.MF.0224.16
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Rogawski MA, Tofighy A, White HS, Matagne A, Wolff C. Current understanding of the mechanism of action of the antiepileptic drug lacosamide. Epilepsy Res. 2015; 110: 189-205.
2. Kanner MA, Ashman E, Gloss D et al. Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs II: Treatment- resistant epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2018; 91(2): 82-90.
3. Epilepsies in children, young people and adults. NICE guideline [NG217].
4. Rejdak K, Mazurkiewicz-Bełdzińska M, Błaszczyk B et al. Diagnostyka i leczenie padaczki – wytyczne Sekcji Padaczki Polskiego Towarzystwa Neurologicznego. Pol. Przegl. Neurol. 2022; 18(4): 201-19.
5. Jędrzejczak J, Majkowska-Zwolińska B, Ryglewicz B et al. Zalecenia Polskiego Towarzystwa Epileptologii dotyczące leczenia napadów padaczkowych u dorosłych. Aktualizacja. Pol. Przegl. Neurol 2020; 16(3): 129-144.
6. Makinen J, Peltola J, Raitanen J et al. Comparative effectiveness of eight antiepileptic drugs in adults with focal refractory epilepsy: the influence of age, gender, and the sequence in which drugs were introduced onto the market. J Neurol. 2017; 264(7): 1345-53.
7. Yang C, Peng Y, Zhang L et al. Safety and Tolerability of Lacosamide in Patients With Epilepsy: A Systematic Review and Meta-Analysis. Front Pharmacol. 2021; 12: 694381.
8. Fishman J, Martin M, Labiner DM et al. Healthcare resource utilization and costs before and after lacosamide initiation as adjunctive therapy among patients with epilepsy in the United States. Epilepsy Behavior 2019; 99: 106331.
9. Baulac M, Rosenow F, Toledo M et al. Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurol. 2017; 16(1): 43-54.
10. Ben-Menachem E, Biton V, Jatuzis D et al. Efficacy and Safety of Oral Lacosamide as Adjunctive Therapy in Adults with Partial-Onset Seizures. Epilepsia 2007; 48(7): 1308-17.
11. Halász P, Kälviäinen R, Mazurkiewicz-Beldzińska M et al. Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial. Epilepsia 2009; 50(3): 443-53.
12. Chung S, Sperling MR, Biton V et al. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia 2010; 51(6): 958-67.
13. Mintzer S, Dimova S, Zhang Y et al Effects of lacosamide and carbamazepine on lipids in a randomized trial. Epilepsia 2020; 61: 2696-2704.
14. Lattanzi S, Trinka E, Zaccara G et al. Third-Generation Antiseizure Medications for Adjunctive Treatment of Focal-Onset Seizures in Adults: A Systematic Review and Network Meta-analysis. Drugs. 2022; 82(2): 199-218.
15. Charakterystyka produktu leczniczego Lacosamide Lacosamide z dnia 10.07.2023 r.
16. Cawello W. Clinical pharmacokinetic and pharmacodynamic profile of lacosamide. Clin Pharmacokinet. 2015; 54(9): 901-14.
17. Johannessen SI, Landmark CJ. Antiepileptic drug interactions – principles and clinical implications. Curr Neuropharmacol. 2010; 8(3): 254-67.
18. Del Bianco, Placidi F, Liguori C et al. Long-term efficacy and safety of lacosamide and levetiracetam monotherapy in elderly patients with focal epilepsy: A retrospective study. Epilepsy Behavior. 2019; 94: 178-82.
19. Rosenow F., Brandt C, Bozorg A et al. Lacosamide in patients with epilepsy of cerebrovascular etiology. Acta Neurol Scand. 2020; 141: 473-82.
20. Schmitz B, Dimova S, Zhang Y et al. Tolerability and efficacy of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed epilepsy and concomitant psychiatric conditions: Post hoc analysis of a prospective, randomized, double-blind trial. Epilepsy Research 2020; 159: 106220.
21. Toniolo S, Di Lorenzo F, Bozzali M et al. The impact of lacosamide on mood disorders in adult patients with epilepsy: A systematic review. Epilepsy Behavior. 2020; 111: 107179.
22. Pozzi M, Zanotta M, Epifanio R et al. Lacosamide effectiveness and tolerability in patients with drug-resistant epilepsy and severe disability under polytherapy: Therapy optimization as emerging from an observational study. Epilepsy Behavior. 2022; 128: 108598.
23. Kleist A, Kerling F, Hamer H et al. Lacosamide in patients with intellectual disability and refractory epilepsy. Acta Neurologica Belgica 2019; 119: 423-30.
24. Li KY, Huang LC, Chang YP et al. The effects of lacosamide on cognitive function and psychiatric profiles in patients with epilepsy. Epilepsy Behav. 2020; 113: 107580.
25. Mo F, Meletti S, Belcastro V et al. Lacosamide in monotherapy in BTRE (brain tumor‑related epilepsy): results from an Italian multicenter retrospective study. J Neurooncol. 2022; 157: 551-59.
26. Ruda R, Houillier C, Maschio M et al. Effectiveness and tolerability of lacosamide as add-on therapy in patients with brain tumor-related epilepsy: Results from a prospective, noninterventional study in European clinical practice (VIBES). Epilepsia 2020; 61: 647-656.
2. Kanner MA, Ashman E, Gloss D et al. Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs II: Treatment- resistant epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2018; 91(2): 82-90.
3. Epilepsies in children, young people and adults. NICE guideline [NG217].
4. Rejdak K, Mazurkiewicz-Bełdzińska M, Błaszczyk B et al. Diagnostyka i leczenie padaczki – wytyczne Sekcji Padaczki Polskiego Towarzystwa Neurologicznego. Pol. Przegl. Neurol. 2022; 18(4): 201-19.
5. Jędrzejczak J, Majkowska-Zwolińska B, Ryglewicz B et al. Zalecenia Polskiego Towarzystwa Epileptologii dotyczące leczenia napadów padaczkowych u dorosłych. Aktualizacja. Pol. Przegl. Neurol 2020; 16(3): 129-144.
6. Makinen J, Peltola J, Raitanen J et al. Comparative effectiveness of eight antiepileptic drugs in adults with focal refractory epilepsy: the influence of age, gender, and the sequence in which drugs were introduced onto the market. J Neurol. 2017; 264(7): 1345-53.
7. Yang C, Peng Y, Zhang L et al. Safety and Tolerability of Lacosamide in Patients With Epilepsy: A Systematic Review and Meta-Analysis. Front Pharmacol. 2021; 12: 694381.
8. Fishman J, Martin M, Labiner DM et al. Healthcare resource utilization and costs before and after lacosamide initiation as adjunctive therapy among patients with epilepsy in the United States. Epilepsy Behavior 2019; 99: 106331.
9. Baulac M, Rosenow F, Toledo M et al. Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurol. 2017; 16(1): 43-54.
10. Ben-Menachem E, Biton V, Jatuzis D et al. Efficacy and Safety of Oral Lacosamide as Adjunctive Therapy in Adults with Partial-Onset Seizures. Epilepsia 2007; 48(7): 1308-17.
11. Halász P, Kälviäinen R, Mazurkiewicz-Beldzińska M et al. Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial. Epilepsia 2009; 50(3): 443-53.
12. Chung S, Sperling MR, Biton V et al. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia 2010; 51(6): 958-67.
13. Mintzer S, Dimova S, Zhang Y et al Effects of lacosamide and carbamazepine on lipids in a randomized trial. Epilepsia 2020; 61: 2696-2704.
14. Lattanzi S, Trinka E, Zaccara G et al. Third-Generation Antiseizure Medications for Adjunctive Treatment of Focal-Onset Seizures in Adults: A Systematic Review and Network Meta-analysis. Drugs. 2022; 82(2): 199-218.
15. Charakterystyka produktu leczniczego Lacosamide Lacosamide z dnia 10.07.2023 r.
16. Cawello W. Clinical pharmacokinetic and pharmacodynamic profile of lacosamide. Clin Pharmacokinet. 2015; 54(9): 901-14.
17. Johannessen SI, Landmark CJ. Antiepileptic drug interactions – principles and clinical implications. Curr Neuropharmacol. 2010; 8(3): 254-67.
18. Del Bianco, Placidi F, Liguori C et al. Long-term efficacy and safety of lacosamide and levetiracetam monotherapy in elderly patients with focal epilepsy: A retrospective study. Epilepsy Behavior. 2019; 94: 178-82.
19. Rosenow F., Brandt C, Bozorg A et al. Lacosamide in patients with epilepsy of cerebrovascular etiology. Acta Neurol Scand. 2020; 141: 473-82.
20. Schmitz B, Dimova S, Zhang Y et al. Tolerability and efficacy of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed epilepsy and concomitant psychiatric conditions: Post hoc analysis of a prospective, randomized, double-blind trial. Epilepsy Research 2020; 159: 106220.
21. Toniolo S, Di Lorenzo F, Bozzali M et al. The impact of lacosamide on mood disorders in adult patients with epilepsy: A systematic review. Epilepsy Behavior. 2020; 111: 107179.
22. Pozzi M, Zanotta M, Epifanio R et al. Lacosamide effectiveness and tolerability in patients with drug-resistant epilepsy and severe disability under polytherapy: Therapy optimization as emerging from an observational study. Epilepsy Behavior. 2022; 128: 108598.
23. Kleist A, Kerling F, Hamer H et al. Lacosamide in patients with intellectual disability and refractory epilepsy. Acta Neurologica Belgica 2019; 119: 423-30.
24. Li KY, Huang LC, Chang YP et al. The effects of lacosamide on cognitive function and psychiatric profiles in patients with epilepsy. Epilepsy Behav. 2020; 113: 107580.
25. Mo F, Meletti S, Belcastro V et al. Lacosamide in monotherapy in BTRE (brain tumor‑related epilepsy): results from an Italian multicenter retrospective study. J Neurooncol. 2022; 157: 551-59.
26. Ruda R, Houillier C, Maschio M et al. Effectiveness and tolerability of lacosamide as add-on therapy in patients with brain tumor-related epilepsy: Results from a prospective, noninterventional study in European clinical practice (VIBES). Epilepsia 2020; 61: 647-656.